Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2023

Impact of 6-Week Treatment With Lotilaner Ophthalmic Solution, 0.25% on Eyes With Severe Demodex Blepharitis

Mitchell Shultz, MD

Show Description +

Mitchell Shultz, MD, shares results of a post-hoc analysis from the Saturn 2 trials exploring treatment of Demodex Blepharitis. Dr. Shultz is hopeful that this treatment will have a positive impact on patients suffering with Demodex Blepharitis.

Posted: 11/16/2023

Keywords:

Demodex blepharitis

•

lotilaner

Up Next

Walking Over a Flat Earth: A Jump Toward Diversity, Equity, and Inclusion (DEI)

Walking Over a Flat Earth: A Jump Toward Diversity, Equity, and Inclusion (DEI)

Basil Williams, MD

$Rethinking Refractive Surgery: What’s New In 2023?$

Rethinking Refractive Surgery: What’s New In 2023?

George O. Waring IV, MD, FACS

Intracameral Low Molecular Weight Heparin for DMEK: A Pilot Safety Study

Intracameral Low Molecular Weight Heparin for DMEK: A Pilot Safety Study

Rahul Tonk, MD, MBA

Combination Therapy in the Treatment of Dry Eye vs. Traditional Cyclosporine

Combination Therapy in the Treatment of Dry Eye vs. Traditional Cyclosporine

John A. Hovanesian, MD

Wet AMD Gene Therapy at 3 Years: Ixo-vec

Wet AMD Gene Therapy at 3 Years: Ixo-vec

Carl D. Regillo, MD, FACS

Pegcetacoplan Extension Study Update

Pegcetacoplan Extension Study Update

Jeffrey S. Heier, MD

Two Years of Treatment with Avacincaptad Pegol

Two Years of Treatment with Avacincaptad Pegol

Arshad M. Khanani, MD, MA

Efficacy of Faricimab with PEDs Revealed

Efficacy of Faricimab with PEDs Revealed

Jennifer I. Lim, MD

Genetics: Now or Later

Genetics: Now or Later

Inas Aboobakar, MD

New Glaucoma Devices in the Pipeline

New Glaucoma Devices in the Pipeline

Matt Schlenker, MD

Virtual Visual Fields: Are They Ready for Prime Time?

Virtual Visual Fields: Are They Ready for Prime Time?

Steven R. Sarkisian Jr, MD

Cutting-Edge Translational Research From the Next Generation

Cutting-Edge Translational Research From the Next Generation

Jodhbir Singh Mehta, MD, PhD

Visual Outcomes With a Small-Aperture IOL in Post-Radial Keratotomy Patients

Visual Outcomes With a Small-Aperture IOL in Post-Radial Keratotomy Patients

Sudhinder Koushik, MD

Drug-Eluting IOLs

Drug-Eluting IOLs

Kenneth Mandell, MD, PhD

Pearls for Subretinal Gene Therapy

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA

A CRISPR Gene Editing Update

A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Tackling TRDs with Limited Membranectomy

Tackling TRDs with Limited Membranectomy

John W. Kitchens, MD

Working Toward Diversity in Retina Clinical Trials

Working Toward Diversity in Retina Clinical Trials

Adrienne W. Scott, MD

Diversity in Ocular Oncology

Diversity in Ocular Oncology

Basil K. Williams Jr, MD

The Latest in Retina Surgical Instrumentation

The Latest in Retina Surgical Instrumentation

David R. Chow, MD

Update on Glaucoma Lasers

Update on Glaucoma Lasers

Aaki Shukla, MD, and Mary Qiu, MD

Back to All Videos

Impact of 6-Week Treatment With Lotilaner Ophthalmic Solution, 0.25% on Eyes With Severe Demodex Blepharitis

Mitchell Shultz, MD

Mitchell Shultz, MD, shares results of a post-hoc analysis from the Saturn 2 trials exploring treatment of Demodex Blepharitis. Dr. Shultz is hopeful that this treatment will have a positive impact on patients suffering with Demodex Blepharitis.

Posted: 11/16/2023

Keywords:

Demodex blepharitis

•

lotilaner

Please log in to leave a comment.

More From AAO: 2023 Coverage

Pearls for Subretinal Gene Therapy

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA

A CRISPR Gene Editing Update

A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Tackling TRDs with Limited Membranectomy

Tackling TRDs with Limited Membranectomy

John W. Kitchens, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2023.